Pharmaids Pharmaceuticals Ltd
₹ 55.6
-2.87%
19 Jun
1:13 p.m.
About
Incorporated in 1989, Pharmaids Pharmaceuticals Ltd manufactures Bulk Drugs and Intermediaries.
Key Points
- Market Cap ₹ 196 Cr.
- Current Price ₹ 55.6
- High / Low ₹ 87.5 / 31.9
- Stock P/E
- Book Value ₹ 18.1
- Dividend Yield 0.00 %
- ROCE -6.87 %
- ROE -10.8 %
- Face Value ₹ 10.0
Pros
Cons
- Stock is trading at 3.15 times its book value
- Company has low interest coverage ratio.
- Promoter holding is low: 5.22%
- Company has a low return on equity of -15.3% over last 3 years.
- Promoter holding has decreased over last 3 years: -30.2%
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Loading peers table ...
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1.39 | 1.73 | 1.68 | 1.20 | 0.45 | 0.56 | 0.00 | 8.55 | 3.94 | 0.00 | 0.03 | 2.34 | |
| 1.83 | 1.82 | 2.03 | 1.54 | 0.84 | 0.67 | 0.34 | 8.45 | 3.81 | 9.89 | 6.41 | 9.60 | |
| Operating Profit | -0.44 | -0.09 | -0.35 | -0.34 | -0.39 | -0.11 | -0.34 | 0.10 | 0.13 | -9.89 | -6.38 | -7.26 |
| OPM % | -31.65% | -5.20% | -20.83% | -28.33% | -86.67% | -19.64% | 1.17% | 3.30% | -21,266.67% | -310.26% | ||
| 0.16 | 0.12 | 0.05 | 0.53 | 0.02 | 0.01 | 0.00 | 0.03 | 0.02 | 0.00 | 0.80 | 1.02 | |
| Interest | 0.01 | 0.00 | 0.03 | 0.04 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.33 | 2.15 |
| Depreciation | 0.08 | 0.14 | 0.10 | 0.06 | 0.00 | 0.05 | 0.04 | 0.04 | 0.01 | 0.02 | 0.18 | 0.20 |
| Profit before tax | -0.37 | -0.11 | -0.43 | 0.09 | -0.37 | -0.15 | -0.38 | 0.09 | 0.14 | -9.91 | -6.09 | -8.59 |
| Tax % | -2.70% | -36.36% | -6.98% | -33.33% | 5.41% | 20.00% | -107.89% | 0.00% | 0.00% | -23.71% | -18.72% | -15.25% |
| -0.35 | -0.07 | -0.40 | 0.11 | -0.39 | -0.18 | 0.03 | 0.09 | 0.15 | -7.56 | -4.95 | -7.28 | |
| EPS in Rs | -1.03 | -0.21 | -1.17 | 0.32 | -1.15 | -0.53 | 0.03 | 0.09 | 0.15 | -3.52 | -1.40 | -2.06 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 3% |
| 5 Years: | % |
| 3 Years: | -16% |
| TTM: | 7700% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | -47% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 32% |
| 5 Years: | 63% |
| 3 Years: | 76% |
| 1 Year: | 11% |
| Return on Equity | |
|---|---|
| 10 Years: | -13% |
| 5 Years: | -13% |
| 3 Years: | -15% |
| Last Year: | -11% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 3.36 | 3.36 | 3.36 | 3.36 | 3.36 | 10.27 | 10.27 | 10.27 | 10.27 | 21.44 | 35.27 | 35.27 |
| Reserves | -1.55 | -1.65 | -2.05 | -1.94 | -2.32 | -1.87 | -1.84 | -1.74 | -1.60 | 0.98 | 35.79 | 28.52 |
| 0.36 | 0.30 | 0.48 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 12.93 | 39.71 | |
| 0.72 | 0.51 | 0.51 | 0.60 | 0.26 | 0.27 | 0.03 | 0.59 | 2.44 | 2.14 | 1.00 | 15.19 | |
| Total Liabilities | 2.89 | 2.52 | 2.30 | 2.02 | 1.30 | 8.67 | 8.46 | 9.12 | 11.11 | 24.56 | 84.99 | 118.69 |
| 0.62 | 0.46 | 0.44 | 0.00 | 0.00 | 0.08 | 0.08 | 0.04 | 0.03 | 0.11 | 16.55 | 24.18 | |
| CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.45 | 0.45 | 0.45 | 0.45 | 2.00 | 2.30 | 3.51 |
| Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 3.27 | 52.60 | 52.61 |
| 2.27 | 2.06 | 1.86 | 2.02 | 1.30 | 8.14 | 7.93 | 8.63 | 10.63 | 19.18 | 13.54 | 38.39 | |
| Total Assets | 2.89 | 2.52 | 2.30 | 2.02 | 1.30 | 8.67 | 8.46 | 9.12 | 11.11 | 24.56 | 84.99 | 118.69 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 0.08 | 0.21 | 0.02 | 0.33 | -0.21 | -0.10 | -0.75 | 0.41 | -0.26 | -4.02 | -3.44 | -7.72 | |
| 0.00 | -0.01 | -0.08 | 0.33 | -0.09 | 0.00 | 0.66 | -0.23 | 0.47 | -4.95 | -72.51 | -18.90 | |
| -0.10 | -0.13 | 0.05 | -0.22 | -0.07 | -0.03 | 0.00 | 0.00 | 0.00 | 21.31 | 65.66 | 24.64 | |
| Net Cash Flow | -0.02 | 0.06 | -0.01 | 0.43 | -0.37 | -0.13 | -0.09 | 0.18 | 0.21 | 12.35 | -10.29 | -1.99 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 330.86 | 234.19 | 232.47 | 240.29 | 421.78 | 580.09 | 11.95 | 124.14 | 0.00 | 24.96 | ||
| Inventory Days | 104.29 | 102.77 | 91.25 | 130.75 | 0.00 | 0.00 | 16.55 | 90.99 | 0.00 | 4,197.50 | 1,774.15 | |
| Days Payable | 197.40 | 145.29 | 138.45 | 245.15 | 22.37 | 236.18 | 0.00 | 2,066.52 | ||||
| Cash Conversion Cycle | 237.75 | 191.67 | 185.27 | 125.89 | 421.78 | 580.09 | 6.14 | -21.05 | 4,197.50 | -267.41 | ||
| Working Capital Days | 249.46 | 200.43 | 193.36 | 161.21 | 227.11 | 2,652.77 | 2.99 | -17.60 | 16,425.00 | -447.67 | ||
| ROCE % | -15.06% | -5.26% | -21.05% | -24.30% | -30.08% | -3.18% | -4.52% | 1.06% | 1.63% | -63.75% | -10.83% | -6.87% |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
24 May - Copies of Newspaper publication of Audited Financial Results (Consolidated and standalone) for the quarter and year ended 31st March 2025.
-
Board Meeting Outcome for Audited Financial Results For The Quarter And Year Ended March 31St, 2025
23 May - Audited standalone and consolidated financial results for FY ended March 31, 2025 approved and published.
- Submission Of Audited Financial Results Along With Auditors Report For The Quarter And Year Ended 31St March 2025 23 May
-
Board Meeting Intimation for Consideration And Approval Of Audited Financial Results (Standalone And Consolidated) For The Quarter And Year Ended 31St March 2025.
20 May - Board meeting on May 23 to approve audited results; trading window closed till 48 hours post announcement.
-
Compliances-Reg.24(A)-Annual Secretarial Compliance
15 May - Annual Secretarial Compliance Report confirms Pharmaids' full regulatory compliance for FY ended March 31, 2025.
Annual reports
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
-
Financial Year 2010
from bse
Product Portfolio:
a) Specialty Chemicals:[1] Retinol, DL Alpha Tocopherol, D-Pantothenate, Cyanocobalamin, Pyridoxine Hcl, Thiamine, Nicotinic Acid, Water Sol. Vitamin E, Coenzyme Q10, D-Biotin
b) Skin Care:[2] Best care hands, Hands Sanitizer, Moisturizing Cream, Skin-Sure Plus, Skin-Sure Ultra, Alcohol Gel, Barrier Cream
c) Hospital Care:[3] Xepi Rub M, Facein Spray, Sod Hypochlorite, Sanmedin, Strumen-G, Strumen TRIACID, Facein Eco, Facein Power, Facein Spray, Sod Hypochlorite, Wipes, PPE
d) Generics:[4] Linzomust, Ceforoot 1.5g, Trendyclav-L, Cobasure Gold 2ML INJ, Benfoshine, Amplimmune, Thiaxa T8, Molprime SR, Citibrain-Plus, Duojoint